TICKERNERD
Menu
KMDAKMDAHealthcare · Drug Manufacturers - Specialty & Generic

KMDA Stock Forecast: Kamada Ltd. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$7.89
−2.71% on the day

The 3 Wall Street analysts covering Kamada Ltd. hold a median 12-month price target of $14 — +77.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$468.0M
Ticker Nerd rank
93 / 100
Median analyst target
$14
Analysts covering
3
Revenue$54.9M+22.7% y/y
Operating income$9.5M
Net income$9.3M
Free cash flow$16.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.7%
1M
−7.6%
YTD
+17.3%
1Y
+24.5%
From 52W high
−11.1%
From 52W low
+25.5%
$6.29
$8.87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KMDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kamada Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
94
Momentum
80
Revisions
72
Volatility
68
Growth
62
Accruals
55
Size
54
Issuance
45

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (45): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KMDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KMDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6.00$8.00$10.00$12.00$14.00$16.00Jan 26Apr 26Jul 26Oct 26KMDAHigh $15Median $14Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $11Median $14High $15

The green dot is the last close — the median target sits +77.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Dec 2025HC Wainwright & Co.MaintainsBuy$11 → $13
15 May 2025BenchmarkReiteratesBuy—
21 Mar 2025BenchmarkInitiatesBuy—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
3 July 2024StifelInitiatesBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
7 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
17 Aug 2023HC Wainwright & Co.ReiteratesBuy—
25 May 2023HC Wainwright & Co.ReiteratesBuy—
16 Mar 2023HC Wainwright & Co.ReiteratesBuy—
2 Feb 2018Chardan CapitalInitiatesBuy—
13 Nov 2015JefferiesMaintainsBuy—
25 June 2013JefferiesInitiatesBuy—
25 June 2013Morgan StanleyInitiatesEqual-Weight—
25 June 2013OppenheimerInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KMDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KMDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Kamada Ltd. returned +24.5% against +17.7% for the S&P 500, dividends included.

KMDA vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140Jan 26Apr 26Jul 26Oct 26KMDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KMDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+11.7%
Analysts raising
4
Analysts cutting
0
Fundamentals

Kamada Ltd. (KMDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.3×

Cheaper than 34% of US stocks

Price / sales
2.4×

Cheaper than 46% of US stocks

Price / book
1.7×

Cheaper than 48% of US stocks

EV / EBITDA
9.9×

Cheaper than 37% of US stocks

Growth & margins
Revenue growth (YoY)
22.7%

Higher than 72% of US stocks

Earnings growth (YoY)
25.6%

Higher than 63% of US stocks

Gross margin
40.9%

Higher than 51% of US stocks

Operating margin
17.3%

Higher than 76% of US stocks

Net margin
11.6%

Higher than 73% of US stocks

Returns & dividend
Return on equity
8.4%

Higher than 60% of US stocks

Return on assets
4.6%

Higher than 74% of US stocks

Dividend yield
8.4%

Higher than 96% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kamada Ltd. (KMDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kamada Ltd. has a market value of $468.0M and an enterprise value of $411.1M.

  • Revenue in the twelve months to 30 June 2026: $191.8M. The latest quarter grew 22.7% year on year.

  • Net income over the same four quarters: $22.3M, a 11.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.38.

  • Free cash flow in the twelve months to 30 June 2026: $26.3M.

  • Kamada Ltd. spent $14.4M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 57.7M.

  • Trailing P/E: 21.3×; forward P/E: 14.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 8.38%, paying out 66% of earnings.

  • Kamada Ltd. employs 462 people — $415K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

KMDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
KMDAKamada Ltd.$468.0M
93
EOLSEvolus, Inc.$480.1M
89
TKNOAlpha Teknova, Inc.$469.1M
96
GLASGlass House Brands, Inc.$427.3M
37
TLRYTilray Brands, Inc.$558.6M
14
CGCCanopy Growth Corp.$402.5M
42
AQSTAquestive Therapeutics, Inc.$578.6M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kamada Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KMDA news & analysis

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

GlobeNewsWire · 6 Oct 2026positive

Kamada announced the launch of two additional biosimilar products in Israel, expanding its portfolio commercialized in Israel and the MENA region. The company expects the portfolio to generate approximately $10 million in annual revenue in 2028 and approximately $20 million-$25 million by 2030.

Why it matters — The launches expand Kamada’s biosimilar offering, and the company provided revenue expectations for the growing portfolio.

Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth

MarketBeat · 27 Sept 2026positive

Kamada presented its growth strategy and financial outlook, highlighting demand for specialty plasma-derived therapies and a plan to expand through product sales, distribution agreements, plasma supply, and potential acquisitions.

Why it matters — KMDA watchers would care because the presentation signals the company's growth direction and strategic focus within its plasma-derived product portfolio.

CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand

GlobeNewsWire · 17 Sept 2026positive

The CDC reported a significant year-over-year increase in U.S. rabies exposures and anti-rabies immunoglobulin use. Kamada confirmed it has sufficient KedRAB® supply, one of only two FDA-approved products in the U.S. market, to meet increased demand. Kamada Ltd. issued the announcement on September 17, 2026.

Why it matters — KMDA watchers would care because rising rabies exposure demand could increase utilization of Kamada's KedRAB, one of only two FDA-approved products in a U.S. market estimated at $200 million annually.

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

Kamada Ltd. announced that CEO Amir London will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, being held at the Lotte New York Palace Hotel. The announcement was made on September 10, 2026.

Why it matters — A KMDA watcher would care because the CEO's presentation at a major investment conference offers an opportunity for the company to update investors on its biopharmaceutical portfolio and specialty plasma-derived business.

Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders

GlobeNewsWire · 3 Sept 2026neutral

Kamada announced it has obtained a tax ruling from the Israel Tax Authority regarding the withholding tax procedures for its previously announced cash dividend of $0.17 per share, totaling approximately $9.8 million, scheduled to be paid on September 17, 2026. The ruling addresses tax treatment for the dividend to shareholders of record as of August 27, 2026.

Why it matters — KMDA watchers would care because the tax ruling clarifies the withholding tax implications for the upcoming cash dividend, which affects the net amount shareholders receive.

FAQ

Frequently asked questions about KMDA stock

What is the KMDA stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Kamada Ltd. have a median 12-month price target of $14, with estimates ranging from $11 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KMDA stock a buy right now?

Of the 3 analysts covering Kamada Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kamada Ltd. 93 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KMDA?

As at 6 Oct 2026, Kamada Ltd. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will KMDA stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +77.4% from the last close, and Ticker Nerd's factor model ranks Kamada Ltd. 93 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KMDA stock forecast for 2030?

No analyst covering Kamada Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KMDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $15 over the next 12 months.

How has KMDA stock performed over the past year?

Kamada Ltd. returned +24.5% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kamada Ltd. do?

Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics.

What is the latest news on KMDA?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel". Kamada announced the launch of two additional biosimilar products in Israel, expanding its portfolio commercialized in Israel and the MENA region. The company expects the portfolio to generate approximately $10 million in annual revenue in 2028 and approximately $20 million-$25 million by 2030.

Company

About Kamada Ltd.

Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics. Kamada Ltd. develops, manufactures, and markets a portfolio of marketed products for rare and serious conditions, with treatments used in areas such as lung disease, immunology, infectious disease prophylaxis, and critical care. The company’s commercial offering includes proprietary plasma-derived therapies and a distribution segment that markets additional biopharmaceutical products in selected international markets. Kamada Ltd. also operates manufacturing capabilities centered on plasma protein purification and sterile production, supporting its vertically integrated business model. Its products are sold through partners, distributors, hospitals, pharmacies, and healthcare organizations across multiple countries, making the company a specialized supplier within the global plasma therapeutics market.

462 employees · Israel · https://www.kamada.com